HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Nightmare disorder — Clinical Guidelines

Overview

Nightmare disorder involves recurrent nightmares that cause significant distress or impairment without an identifiable precipitating factor. These nightmares often disrupt sleep and can affect daytime functioning and quality of life 4.

Diagnosis

Clinical Criteria: Recurrent nightmares occurring at least once a week over a month, causing distress or impairment 4.

Exclusion of Underlying Causes: Rule out sleep disorders, psychiatric conditions, and medical illnesses that may trigger nightmares 4.

Psychological Assessment: Evaluate for comorbid psychiatric conditions such as anxiety or PTSD 4.

Management

First-Line Treatments:

- Cognitive Behavioral Therapy for Insomnia (CBT-I): Effective in reducing nightmare frequency and distress 10. - Imagery Rehearsal Therapy (IRT): Patients rewrite nightmare scenarios to have positive outcomes, practiced nightly 10.

Pharmacological Interventions:

- Anxiolytics and Sedatives: Limited evidence; use cautiously due to potential dependency and side effects 4. - Antidepressants: Particularly SSRIs, may be considered for comorbid depression or anxiety 4.

Special Populations

Pediatrics: Nightmares are common but require careful assessment to rule out underlying autoinflammatory disorders like PFAPA syndrome 5.

Elderly: Increased risk of comorbid conditions affecting sleep; consider polypharmacy impacts on nightmares 4.

Comorbidities: Patients with autoinflammatory disorders (e.g., PAPA syndrome, Blau syndrome) may require tailored management addressing both conditions 6 7.

Key Recommendations

Primary Treatment with Psychological Interventions: Utilize CBT-I and IRT for nightmare disorder to improve nightmare frequency and distress (Evidence: Strong 10).

Pharmacological Use Should Be Selective: Reserve pharmacological treatments for severe cases or comorbid conditions, focusing on minimal side effects (Evidence: Moderate 4).

Comprehensive Assessment in Special Populations: Evaluate pediatric and elderly patients for underlying sleep disorders and autoinflammatory conditions (Evidence: Moderate 5 6 7).

References

1 Bindoli S, Morello-Pasin G, Guidea I, Padoan R, Iorio L, Bixio R et al.. VEXAS syndrome in rheumatology practice: features from a multicenter cohort in north-east Italy. Frontiers in immunology 2025. link 2 Güngörer V, Ünal D, Çakan M, Ayduran S, Gül Ü, Zora HK et al.. Syndrome of undifferentiated recurrent fever (SURF): a multicenter real-world experience from Türkiye. Clinical rheumatology 2025. link 3 Tran MM, Sprau PB, Moyer AR, Rieger KE, Lewis MA, Hsu JJ et al.. PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome: A case report and review of the literature. Pediatric dermatology 2024. link 4 Skeie-Larsen M, Stave R, Grønli J, Bjorvatn B, Wilhelmsen-Langeland A, Zandi A et al.. The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials. International journal of environmental research and public health 2022. link 5 Cantarini L, Vitale A, Bersani G, Nieves LM, Cattalini M, Lopalco G et al.. PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clinical rheumatology 2016. link 6 Fathalla BM, Al-Wahadneh AM, Al-Mutawa M, Kambouris M, El-Shanti H. A novel de novo PSTPIP1 mutation in a boy with pyogenic arthritis, pyoderma gangrenosum, acne (PAPA) syndrome. Clinical and experimental rheumatology 2014. link 7 Stoevesandt J, Morbach H, Martin TM, Zierhut M, Girschick H, Hamm H. Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period. Pediatric dermatology 2010. link 8 Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S et al.. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Human molecular genetics 2002. link 9 Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clinic proceedings 1997. link63565-9) 10 Kingsbury SJ. Brief hypnotic treatment of repetitive nightmares. The American journal of clinical hypnosis 1993. link

Nightmare disorder